Bench to bedside Flashcards

1
Q

Order of drug discovery process

A
Discovery - target validation
hit identification
lead identification
lead optimisation
nomination phase
clinical trials - phases I-IV
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What characteristics do we need our drug to have?

A
good bioavailability
good absorption
slow metabolism - allow for absorption
no toxic metabolites
bodily distribution to facilitate access to the target
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Achieving a pharmacodynamic output at a molecular level?

A

enzyme inhibition
receptor antagonism/agonism
Introduce groups which drive up affinity for the target protein to improve potency (lower dose can be given)
Introduce groups which achieve selectivity (reducing toxicity)
H-bonding drives interactions with key amino acids in the target protein
Lipophilic can provide interactions with drug target

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Achieving the correct pharmacokinetic profile to enable access to the target for a sustained time period?

A

ADME
Where the drug goes (i.e. protein bound drug cannot exert effect)
how long it stays in the body (half life)
How it is metabolised

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Ranges of bonds, short, mid, long

and groups typically involved

A
  1. vdW - Short range - aromatic and non-polar aliphatic side groups
  2. H-bond - Mid range - polar, uncharged side groups
    electron- deficient H.
    Electronegative atoms with lone pairs O, F, N
  3. Ionic - long range- NH3 +ve with negative (e.g. O)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Role of halogen in SPR profiles

A

block oxidation but lipophilic so influence water solubility therefore absorption

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Role of hydrophilic groups

A

promote phase II metabolism and renal excretion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

How are hits against the target identified?

A

High throughput assay. Use compound library to identify any “hits”
Target enzyme + substrate = quantifiable signal readout

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

How is inhibitory activity carried out (simple version)?

A

Target enzyme + small molecule inhibitor compared with quantified readouts

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Optimising for potency - ABSORPTION

A

Physical properties and formulation (log D, log P)
solubility
permeability (Caco2)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Optimising for potency - DISTRIBUTION

A
Vd
Bioavailability
Target selectivity
Receptor drug interactions
Protein binding
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Optimising for potency - METABOLISM

A

Modifications - Phase I and Phase II

Renal and hepatic clearance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Optimising for potency - EXCRETION and TOXICITY

A

Toxicology assays - AMES - mutagenicity
HERG - screens for cardiotoxicity/arrhythmias
in vivo safe dosing, toxic dose
IC 50

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

EC50 and IC50 definitions

A

EC50 Half maximal response drug concentration

IC50 concentration of inhibitor where response is reduced by half

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What does DMPK stand for?

A

Drug Metabolism and Pharmacokinetics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is IHC?

A

Immunohistochemistry (IHC) is an important application of monoclonal antibodies to determine the tissue distribution of an antigen of interest in health and disease

17
Q

what occurs in phase 2a trials

A

dose finding and PK in 10s of patients

18
Q

2b trials?

A

confirm efficacy with confidence 10-100 patients

19
Q

binding roles:

  1. Amine
  2. Amides
  3. Carboxylic acids
  4. Esters
  5. Aromatic ring
A
  1. amine HBD/HBA if lone pair available (N)
  2. amide - HB
  3. Carboxylic acid - HB - good ligand for Zn, Ionic bonding
  4. Esters - used to mask polar groups
  5. Aromatic ring - vdWs. Phenol - HB
20
Q

Quick summary of enalapril optimisation

A
  1. Thiol improves potency (but S/Es) so replaced aromatic (S1)
  2. COOH essential for oral administration (salt forming group) - RCOOH + NaOH = RCOONa + H20
  3. Aliphatic S2 occupancy
  4. COOH binds ERG (Zn)
  5. Carboxylic acid too polar (masks as ethyl ester in prodrug)
21
Q

Summary of farnesyl transferase inhibitors

A
  1. Zn bound in FT active site increases nucleophilicity of the Cys thiol group
  2. Thiol co-ordinates Zn and has good affinity for FT site
  3. Aromatic - higher affinity
  4. Free carboxyl - affinity for binding
22
Q

in vivo test for CYP

A

liver hepatocytes + compound = metabolites and any interactions

23
Q

Planar aromatic structures in topoisomerase I inhibitors

and other drug development

A

promote stacking in solude state preventing dissolution
(inert = no salt forming groups => hydrolyse
Tertiary aliphatic amine allows formulation as a salt

24
Q

in vitro testing

  1. pharmacology
  2. PK
  3. Safety (IHC)
A
  1. affinity/potency target test, MOA, effect in complex assay system
  2. PK - Clearance, PAMPA, Caco-2 (permeability), Ussing chamber, Solubility (max absorbed dose), Plasma protein binding
  3. Safety - selectivity - affinity/potency
    specificity - cell lysis
    front-loaded HERG (cardiotoxicity)
    AMES - (carcinogenicity)
25
Q

in vivo testing

  1. pharmacology
  2. PK
  3. Safety
A
  1. Guinea pig model efficacy
  2. Clearance
    Half life
    F
    Vd
  3. Safety - absorbed from efficacy studies